• YM 58483 (BTP2): SOCE Research Overview

  2026-10-03

  A source-grounded overview of YM 58483 (BTP2), covering SOCE biology, immune-signaling applications, salivary-gland fibrosis findings, evidence strength, and key limitations.

• HyperScribe™ T7 Fluorescein RNA Guide

  2026-10-01

  Learn how the HyperScribe™ T7 High Yield Fluorescein RNA Labeling Kit can support transcript-level experiments inspired by the TaCRVP–SlCAT2 redox-defense mechanism, while clarifying what fluorescent RNA can and cannot prove.

• Bufalin, CENPA, and Glycolysis in HCC

  2026-10-01

  A 2026 Molecular and Cellular Endocrinology study connects Bufalin activity with CENPA-regulated glycolysis, PI3K/AKT signaling, and hepatocellular carcinoma cell migration. Its integrated bioinformatics, cell-based, docking, and preliminary xenograft evidence defines a mechanistic hypothesis for further hepatocellular carcinoma treatment research while leaving direct target engagement and clinical relevance unresolved.

• HIV-1 Nuclear Pore Remodeling in Resting T Cells

  2026-09-30

  The reference study shows that HIV-1 cell–cell spread can activate CD4–LCK–CDK1 signaling in resting CD4+ T cells, remodeling nuclear pore complexes to overcome a capsid nuclear-import barrier. This mechanism separates infection permissivity from conventional mitogenic activation and explains why virological synapses are especially efficient for HIV-1 dissemination.

• Polyethylenimine Linear: PEI MW 40,000 Workflows

  2026-09-30

  Build reproducible DNA delivery workflows with Polyethylenimine Linear, PEI MW 40,000, from 96-well reporter assays to scalable recombinant protein production. The same transfection framework can support mechanistic toxicology studies, including assays probing mitochondrial stress, integrated stress responses, and blood-testis barrier biology.

• Antimycin A4 for Reliable Cell Metabolism Assays

  2026-09-29

  This scenario-based guide explains how Antimycin A4 (SKU C8711) can clarify variable viability, proliferation, and mitochondrial metabolism results. It connects mechanism, assay compatibility, protocol controls, data interpretation, and practical product-selection criteria to improve experimental reproducibility.

• Oct4 Enhancer Logic in Pluripotency and Embryogenesis

  2026-09-29

  The reference study uses targeted deletion of the Oct4 distal and proximal enhancers to show that enhancer dependence changes between naive and primed pluripotent states. Its comparison of cultured stem cells with mouse embryos reveals that enhancer dispensability in vitro does not predict developmental sufficiency in vivo.

• Neuroligin 1, D2-MSNs, and Repetitive Behavior

  2026-09-28

  The reference study identifies Neuroligin 1 loss in striatal D2 medium spiny neurons as a driver of excessive self-grooming and digging in mice. Its combination of cell-type-specific activity manipulation, behavioral analysis, single-nucleus RNA sequencing, and protein validation implicates neuronal hyperactivation and PKC overactivation as important mechanistic links.

• Self-Adaptive Nanocarriers for Pancreatic Cancer

  2026-09-28

  The ACS Nano study describes DATCPT, a pH- and ROS-responsive nanocarrier designed to coordinate tumor-cell entry, stromal remodeling, and camptothecin delivery in orthotopic pancreatic cancer. Its findings suggest a way to address several delivery barriers in sequence, while leaving important questions about safety, clinical translation, and the interpretation of ROS measurements for future work.

• PYR-41 for E1 Ubiquitination Research

  2026-09-27

  Use PYR-41 to test how blocking ubiquitin activation affects protein turnover and inflammatory signaling—not as a direct proteasome inhibitor. This practical guide connects dose-finding and pathway controls to recent ESCC B-cell findings while emphasizing the compound’s selectivity limits.

• TPCA-1 for NF-κB and Septic AKI Research

  2026-09-26

  Use TPCA-1 to test whether IKK-2 activity drives inflammatory signaling in septic acute kidney injury models, while separating direct pathway inhibition from the kidney’s adaptive miR-202-5p feedback response. This guide pairs a practical cell-based workflow with controls for pathway engagement, cytokine output, and interpretation limits.

• Tetrahydromagnolol in CB2 Signaling Workflows

  2026-09-25

  Use Tetrahydromagnolol to build receptor-focused CB2 assays, then distinguish receptor pharmacology from downstream cell-motility phenotypes. Its reported potency and separate GPR55 activity offer a practical concentration-guiding framework—not evidence that it blocks the TBXA2R–ERM metastatic pathway.

• Oseltamivir Acid: From Target Inhibition to Assay Logic

  2026-09-25

  Oseltamivir acid is an influenza neuraminidase inhibitor whose effects are best interpreted across enzyme, cell, and viral-spread assays. This guide connects target engagement, H275Y resistance, and carefully bounded cross-domain evidence to practical influenza antiviral research decisions.

• Camostat Mesilate: Protease Selectivity in Context

  2026-09-24

  Camostat Mesilate is a trypsin-like protease inhibitor used to investigate ENaC function and plasmin–TGF-β signaling. This article explains how to distinguish pathway effects from target-specific mechanisms, using recent TMPRSS2 inhibitor research to sharpen assay choices.

• HyperScript RT SuperMix for qPCR in Immune Studies

  2026-09-24

  Connect epigenetic immune-pathway research to a practical two-step qRT-PCR workflow, from RNA input planning to target selection and controls. HyperScript RT SuperMix for qPCR is especially useful when RNA is scarce or structurally challenging, while careful assay design keeps transcript measurements distinct from evidence of pathway activation.

8665 records 2/578 page Previous Next 12345 下5页 Last page